The U.S. Food and Drug Administration (FDA) suspended the drug trial earlier this month after three people died. The drug trial was resumed only days after an investigation into the study.
The drug, JCAR015 is an immunotherapy treatment which uses certain parts of the immune system to fight against cancer cells.
The three deaths related to the investigational drug are believed to be caused by an interaction between multiple drugs.
It is believed that when the trial drug combined with some chemotherapy drugs it caused fatal brain swelling.
Regulators ruled the potential benefits of the drug seem to outweigh the three deaths, and that particular chemotherapy drug is being considered as a treatment of melanoma, lung cancer, and specific oral cancers.